iHub News
3週前
Inspira Technologies Rebrands as QTREX Quantum and Changes Nasdaq Ticker to QTEXMay 19, 2026 10:31 AM
IH Market News The company is shifting its strategic focus toward quantum connectivity infrastructure and advanced electronics manufacturing technologies. Key Investor Takeaways Inspira Technologies (NASDAQ:IINN) will begin trading under the new ticker symbol QTEX on May 20, 2026. The company is changing its corporate name to QTREX Quantum Ltd. as it pivots toward quantum connectivity and advanced electronics manufacturing. QTREX is focusing on its Additively Manufactured Electronics (AME) platform to address hardware challenges in quantum computing systems. The strategy targets next-generation quantum connectivity infrastructure for dilution cryostats used in scalable quantum computing environments. Inspira said it will continue developing portions of its medical technology business while seeking opportunities to monetize certain healthcare assets. Why IINN Stock Is In Focus Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) announced that its ordinary shares will begin trading under the new Nasdaq ticker symbol QTEX on May 20, 2026, following a corporate name change to QTREX Quantum Ltd.The company’s warrants will begin trading under the symbol QTEXW, while existing symbols IINN and IINNW will remain active through the close of trading on May 19.According to the company, the rebranding reflects a strategic shift toward its Additively Manufactured Electronics (AME) technology platform, which it plans to use for advanced manufacturing applications, high-performance electronics and quantum connectivity infrastructure.QTREX said it is targeting one of the major hardware challenges in quantum computing: connectivity inside dilution cryostats.The company stated that conventional wiring systems inside quantum computing environments create issues related to heat, radio frequency loss, noise and mechanical complexity as systems scale.Its proposed solution involves developing monolithic interconnect structures designed to integrate conductors, shielding, RF dielectrics, thermal management and routing into a unified system intended for next-generation quantum computing infrastructure. Why This Matters For Investors The announcement may matter to investors because it signals a significant strategic repositioning away from Inspira’s historical focus on medical technologies toward emerging quantum computing infrastructure markets.The shift toward quantum connectivity and advanced electronics manufacturing could place the company within sectors currently attracting heightened investor interest tied to artificial intelligence, high-performance computing and next-generation semiconductor infrastructure.At the same time, the move may also introduce execution risk, as the company is repositioning around technologies that remain early-stage and highly competitive.Investors may also focus on whether QTREX can successfully commercialize its AME platform and differentiate its connectivity solutions within the broader quantum computing ecosystem.The company’s continued involvement in medical technologies while simultaneously pursuing quantum infrastructure opportunities could also raise questions about capital allocation priorities and long-term strategic focus. What To Watch Next Investors will likely monitor: The market reaction to the QTEX ticker transition Further details around commercialization of the AME platform Progress in quantum connectivity and dilution cryostat applications Potential partnerships in defense, aerospace and quantum computing markets Any updates regarding monetization of the company’s medical technology assets Additional disclosures related to revenue strategy and operational execution in its new focus areas Inspira Technologies OXY stock price Original: Inspira Technologies Rebrands as QTREX Quantum and Changes Nasdaq Ticker to QTEX
INV4
9月前
Is Inspira Technologies A Hidden Biotech Jewel?
August 22, 2025
Written by Matt Monaco | Reviewed by Jack Kellogg | Fact-checked by Tim Sykes
Inspira Technologies Oxy B.H.N. Ltd. stocks have been trading up by 13.6 percent boosted by promising FDA designation news.
• By tying up with a premier consulting firm, Inspira is not just expanding its footprint in strategic markets but is also setting itself up for accelerated growth. This timely alliance, especially following the high-profile purchase order, positions the company as a frontrunner in medical innovation.
• The ART100 system, a cutting-edge cardiopulmonary solution, has been chosen by top-tier U.S. hospitals for integration, showcasing its credibility and the potential to revolutionize conventional healthcare practices.
• Inspira’s strategic focus on extending its real-time blood monitoring technology and advanced respiratory support systems is reinforced by a strong partnership with government health sectors, painting a promising picture for its broad-scale adoption.
Profit and Performance: A Closer Look at the Numbers
As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” This golden advice is essential for traders navigating the volatile markets. By exercising patience and waiting for ideal trades instead of hastily jumping into every opportunity, traders are more likely to see long-term success. It’s not about the number of trades one makes but the quality and strategic planning behind each trade, aligning perfectly with Tim Sykes’ seasoned approach.
Inspira Technologies’ recent financial triumphs cannot go unnoticed. With a decisive leap in purchase orders totaling $49.5M, the firm has pivoted from being a budding contender to a formidable player in the biotech realm. The excitement swarms around their ART100 systems—a product with U.S. FDA clearance that beckons a brighter future for many medical institutions globally. Meanwhile, Inspira’s strategic alliance with influential consulting firms only fuels speculation about its rising stock value.
The last quarter’s earnings hinted at clouds of uncertainty with volatile market activity. IINN opened at $1.23 on Aug 21, 2025, climbing its way to $1.25 by the end of the day. Fluctuations are commonplace, with frequent highs and lows—evoking interest yet caution among investors. Their revenue strategies have laid a solid foundation to revive confidence amidst investors.
The financial backbone, according to recent reports, hints at strong equity positions standing tall at over $4M—this capacity might be the very lifeline needed to bolster heavy industry competition. However, with returns on assets and equity staggering in the negatives, there’s room for enhancing operational efficiency. Yet, such weaknesses are often shadows cast by the bright future their groundbreaking technologies promise to bring to fruition.
Deciphering Recent Stock Movements
The buzz surrounding IINN reverberates through recent substantial orders from an African health ministry, cementing Inspira’s resilience and potential. Such large-scale orders illustrate trust not only in product execution but adaptability within varied healthcare ecosystems. Every purchase symbolizes yet another pillar supporting stock surges, reflective of mounting investor belief in the transformative power of Inspira’s technology.
Their expanding global reach, spurred by alliances with market-shaping consultancies, reignites curiosity among stakeholders concerning profitable evolutions in healthcare paradigms. The energy around Inspira’s stock, compounded by strategic and operational prowess, paves the way for more dynamic and productive investment scenarios.
Analyzing market signals and stock volatility, signs point to impending favorable price shifts. Stock behavior often ebbs and flows, responding skeptically to market whispers, yet persistent confidence propelled by health sector accolades remains a mega-force to reckon with. Adaptive strategic initiatives underline Inspira’s unwavering commitment to revolutionizing industry standards, promising a path dotted with significant growth patterns.
Market Impact: Understanding IINN’s Future
A whirlwind of strategic decisions engulf Inspira Technologies’ path today. Their carefully cultivated partnerships and a prolific stream of capital pour optimism into their forecast, even as key financial metrics urge for increased management efficiency. The alignment with robust global trends sharpens their competitive edge, showcasing the value of their niche but mission-critical approach. On the broader financial and stock spectrum, the recent uptrend witnessed could spiral, tempting deeper trading ventures. This shift echoes the wisdom of millionaire penny stock trader and teacher Tim Sykes, who wisely says, “You must adapt to the market; the market will not adapt to you.” Spurts of volatility surface as buying waves clash with periodic sell-offs. However, a bevy of untapped potential, mirroring those orders and consultancy enhancements, allude to more profound stock shifts that bespeak beneficial acquisitions or joint ventures. As equity strategies redefine their terrain, Inspira stands accredited, with its ambitious eyes fixed firmly on distant horizons. IINN, while representing inevitable fluctuations, steadily centers itself within industry dialogues. Here lies a once-overlooked player now strategizing for renewed market dominance—comparable to the heartbeat of innovation pulsating toward a future where benchmarks break, and inspiration springs yet anew.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
https://www.timothysykes.com/news/inspira-technologies-oxy-bhn-ltd-iinn-news-2025_08_22/
$IINN
INV4
9月前
Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market
August 22, 2025
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, has received U.S. Patent approval for low flow rates extracorporeal oxygenation system and methods of use. This patent represents the core technology of the ART500 device, a key asset in the Company’s strategy to penetrate the $20 billion estimated market for advanced respiratory support. This innovation has 16 claims found to be novel.
The patent provides further protection for the underlying core technology of Inspira’s ART500 system, which is designed to provide extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency. This capability targets a large, underserved patient population that requires respiratory support but may not be sick enough for traditional, high-flow ECMO systems, significantly expanding the potential market for Inspira's technology. This approval strengthens Inspira’s intellectual property portfolio and reinforces the Company’s technological leadership in the field of advanced extracorporeal life support.
Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "This patent has profound business implications for Inspira and for our ability to dominate a market with a potential size of $20 billion. We are creating a new therapeutic category for conscious, spontaneously breathing patients. Protecting our intellectual property is a critical pillar of our growth strategy, and this patent approval provides us with a distinct competitive advantage. While our ART100 system is already generating commercial momentum, this move fortifies our future and gives us the clear runway needed to translate our technological leadership into long-term value for our shareholders, and a new standard of care for patients worldwide."
The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500’s functionality, design, and clinical applications. Inspira is pursuing additional patents in major jurisdictions worldwide to expand its intellectual property coverage.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
https://investorshub.advfn.com/stock-market/NASDAQ/inspira-technologies-oxy-IINN/stock-news/96689497/inspira-receives-u-s-patent-approval-for-the-art5
$IINN 💹
INV4
10月前
Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 18, 2025
RA'ANANA, Israel, July 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement.
The notice, dated July 17, 2025, stated that for the 10 consecutive business days from July 2, 2025, through July 16, 2025, the closing bid price of the Company's common shares was at or above $1.00 per share. As a result, Inspira has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now closed.
“This compliance milestone is a direct reflection of the market's growing confidence in our strategic trajectory,” said Dagi Ben-Noon, CEO of Inspira Technologies. “The past few weeks have marked a transformative shift for Inspira, from securing a large commercial order to building a pathway with a government partner for national adoption and global scale up. We are not just evolving; we are transforming into something new, significant, and in a class of its own. We are now fully focused on global distribution, execution, and delivering long-term value to our shareholders.”
Inspira is advancing its government-focused strategy following the successful conclusion of high-level talks, building upon a sequence of foundational milestones. These include the clinical integration of the ART100 in Tier-1 U.S. hospitals, the recent expansion of manufacturing capabilities, and the recently announced $22.5 million purchase order. Collectively, these achievements now serve as a powerful catalyst, accelerating Inspira's ongoing discussions with commercial and governmental entities worldwide.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Inspira Regains Compliance article
$IINN 💹
INV4
11月前
Inspira Achieves All Key Objectives in Previously Announced Government Talks, Forging a Pathway to National Adoption and Global Scale-Up of the ART100
July 10, 2025
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has successfully achieved all key strategic objectives in its high-level talks with a government health authority, located outside of the United States, on July 8, 2025, a meeting previously announced by the Company on July 7, 2025, establishing a definitive pathway for the nationwide adoption of the Company’s ART100 system and creating the foundation for a future global scale-up.
This breakthrough follows a direct invitation from the government, which recognizes the ART100 as a clinically validated, field-proven system, driving the decision to initiate a national integration process.
The newly established pathway defines a strategic framework designed to accelerate the integration of the ART100 into the country’s national emergency infrastructure. Furthermore, it creates the foundation for a global distribution and manufacturing hub, a structure intended to significantly enhance the value and accelerate the execution of the Company’s existing $22.5 million purchase order, as announced on July 2, 2025.
“This achievement is a catalyst that is transforming Inspira into a new kind of company,” said Dagi Ben Noon, Chief Executive Officer of Inspira Technologies. “We are now building the infrastructure for a government-aligned, global commercial platform. Our entire focus is on execution, and we intend to move with a speed and determination that will fundamentally change the scale of our company.”
This development marks a significant validation and acceleration of Inspira’s stated strategy, signaling the Company’s entry into the global government-aligned healthcare infrastructure space.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com.
https://ih.advfn.com/stock-market/NASDAQ/inspira-technologies-oxy-IINN/stock-news/96407693/inspira-achieves-all-key-objectives-in-previously
$IINN 💹
INV4
11月前
Inspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework
July 7, 2025
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it is engaged in high-level talks with a government health authority, located outside of the United States, which are intended to advance the national integration of its FDA-cleared ART100 system as a foundational component of the national emergency infrastructure and to establish a global distribution framework.
The meeting, scheduled for July 8, 2025, is intended to define the key terms and roadmap for this strategic collaboration. These advanced discussions were initiated following a direct invitation from the government of the health authority, which is actively seeking to secure next-generation medical technologies and enhance national emergency readiness.
The government involved is recognized for its extensive commercial ties and diplomatic channels spanning the entire international community. Accordingly, the agenda will also feature the discussion relating to the establishment of a global distribution framework that leverages these unique capabilities with the aim to accelerate and increase the profitability of the $22.5 million purchase order received by Inspira, as announced on July 2, 2025.
Dagi Ben-Noon, CEO of Inspira Technologies, stated: “Engaging in strategic dialogue with national leadership is an important milestone for us and that it reflects the growing recognition that the ART100 is more than a medical device, but rather a vital tool for national preparedness. In parallel, we intend to leverage the government’s international reach to build a global distribution engine that is intended to maximize the profitability of our recent deal and those to come”.
This high-level discussions marks a significant validation and acceleration of Inspira’s stated strategy, signaling a fundamental shift from regional commercial deals to global, government-level partnerships.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
https://ih.advfn.com/stock-market/NASDAQ/inspira-technologies-oxy-IINN/stock-news/96383144/inspira-in-high-level-government-talks-to-advance
$IINN 💹
INV4
11月前
Nice recent news 🗞️ 💹
Inspira’s ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions
June 11, 2025
RA'ANANA, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that its FDA-cleared ART100 system adoption has begun to positively impact commercialization interest and efforts, representing a key milestone and significantly contributes to the Company's commercial validation.
The ART100 system has been successfully integrated into real-world clinical workflows at leading tier-one U.S. hospitals over the past several months. Details of specific hospital deployments are subject to confidentiality, but reflect Tier-1 facilities in the U.S. This clinical use reflects growing confidence in the system’s potential to support patients in critical condition and positions Inspira at the forefront of a rapidly evolving market of life-saving technologies.
The consistent use of the ART100 has prompted a wave of interest from additional U.S. and international healthcare institutions, as well as governmental authorities. The Company is currently engaged in commercial discussions with various stakeholders across multiple regions and is scaling up operational capabilities to support the anticipated adoption of the ART100.
"Over the past several months, the ART100 has been used in real-world settings at leading U.S. hospitals, supporting patients. This clinical use sends a strong message to the global market – that our technology is trusted by physicians, integrated into workflows, and is now driving commercial demand."
— Dagi Ben-Noon, CEO, Inspira Technologies
This announcement builds on Inspira’s global rollout strategy, expanded manufacturing capacity and advanced negotiations with a European government authority. The Company anticipates announcing additional strategic deployments and commercial milestones in the near term.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
https://www.globenewswire.com/news-release/2025/06/11/3097620/0/en/Inspira-s-ART100-in-Use-at-Tier-1-U-S-Hospitals-Generating-Strong-Clinical-Interest-and-Accelerating-Sales-Discussions.html
=================
Inspira Technologies Lands $22.5 Million ART100 Order, Nearing Company's Market Cap in Sales
July 2, 2025
Inspira Technologies has secured a binding $22.5 million purchase order for its ART100 system, marking a pivotal moment for the medical device company. This order, representing a substantial sum when compared to Inspira's market capitalization of $23.8 million, signals the company's clear transition into full-scale revenue generation.
The purchaser is a privately held company based outside the United States, described as a global strategic hub with established commercial ties to government entities and institutional healthcare customers. This suggests a potentially strategic relationship that could unlock further market access for Inspira.
The ART100 system, an FDA-cleared device for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., has seen clinical use in prominent U.S. medical centers. This track record likely played a role in securing the order, which Inspira estimates to be only a small fraction of its total global addressable market.
Inspira's CEO, Dagi Ben-Noon, highlighted the order as a "signal of the broad activation of Inspira's commercial model," affirming market demand and demonstrating real-world execution. The company has already initiated onboarding, logistics, and deployment planning, with full payment of the $22.5 million order expected within 2025.
Looking ahead, Inspira is actively scaling its commercial infrastructure and engaged in advanced negotiations with additional healthcare companies and governmental institutions worldwide. These discussions are anticipated to lead to further commercial agreements in the near term, building on this initial major order.
Why is this newsworthy?
Inspira Technologies secured a $22.5 million purchase order for its FDA-cleared ART100 system, with full payment expected during 2025. This order represents a substantial financial commitment relative to the company's current scale, marking a clear transition into full-scale revenue generation and indicating strong market validation for its technology. The immediate implementation and expectations of further commercial agreements suggest a material and certain financial impact.
What is the key announcement from Inspira?
A binding $22.5 million purchase order for its ART100 system.
When is payment for the order expected?
Full payment of $22.5 million is expected during 2025.
Who placed this order?
A privately held company headquartered outside the U.S., in a global strategic hub, with established commercial ties to government entities and institutional healthcare customers.
What is the ART100 system?
Inspira's FDA-cleared device approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S.
What does Inspira consider this order to signify?
A significant commercial milestone marking a clear transition into full-scale revenue generation and validation of its technology.
What is Inspira's outlook for future commercial agreements?
The company is in advanced negotiations with additional healthcare companies and governmental institutions across multiple regions, with agreements expected in the near term.
How does the company view the market opportunity?
The purchase order represents only a small portion of the total addressable market Inspira is currently targeting globally.
https://www.panabee.com/news/inspira-technologies-lands-22-5-million-art100-order-nearing-company-s-market-cap-in-sal
$IINN 💹
INV4
11月前
Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase
July 2, 2025
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has secured a binding $22.5 million purchase order for its FDA-cleared ART100 system, representing a major commercial inflection point for the Company. The order was placed by a privately held company headquartered outside the United States, in a global strategic hub, with an established track record and active commercial ties to both government entities and institutional healthcare customers.
Under the terms of the binding purchase order, full payment of $22.5 million is to be made during 2025. Inspira and the purchasing organization have initiated onboarding, logistics planning, and deployment scheduling, with immediate implementation.
This purchase order is a significant commercial milestone for Inspira, marking a clear transition into full-scale revenue generation. Inspira estimates that this purchase order represents only a small portion of the total addressable market the Company is currently targeting globally.
"We view this order as a signal of the broad activation of Inspira’s commercial model,” said Dagi Ben-Noon, CEO of Inspira Technologies. “It is a vote of confidence in our technology, confirms market demand, and signals to the market that we are executing in real-world settings. The clinical use of the ART100 in top U.S. medical centers opened the door to this agreement, and it lays the foundation for the next wave of global deployments already underway.”
Inspira is currently in advanced negotiations with additional healthcare companies and governmental institutions across multiple regions. These discussions are progressing toward commercial agreements that are expected to be announced in the near term, further supporting the Company’s commercial expansion strategy.
This announcement follows a series of major company milestones, including successful clinical integration in Tier-1 hospitals, and manufacturing expansion. Inspira is actively scaling its commercial infrastructure to support accelerated pipeline expansion and recurring deployments on a global scale.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
https://ih.advfn.com/stock-market/NASDAQ/inspira-technologies-oxy-IINN/stock-news/96359209/inspira-technologies-secures-22-5-million-purchas
https://inspira-technologies.com/
$IINN 💹
subslover
1年前
Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections
The ex-vivo testing demonstrated significant bacterial reduction for the innovative IV dressing technology aimed at preventing bloodstream infections in critical patients
RA'ANANA, Israel, Feb. 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology, today announced positive initial results from its previously reported collaboration with Ennocure MedTech Ltd. to develop a novel bio-electronic treatment for preventing bloodstream infections.
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated a 95% reduction in bacterial presence within 4 hours, with continued effectiveness observed over a 24-hour period. The technology, which uses physical electric stimulation rather than chemical agents, showed promising results in preventing pathogen growth on treated surfaces.
"We believe that these initial results represent an important milestone in our development of next-generation infection prevention technology," said Dagi Ben-Noon, CEO of Inspira. "With an estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide each year, we believe this novel approach could potentially offer significant advantages in critical care settings."
The bio-electronic technology is being designed to address several key challenges associated with traditional IV dressings, including:
Prevention of bacterial growth through physical rather than chemical means
Potential for extended wear time, reducing frequency of dressing changes
Applicability to both skin surface and cannula areas
Real-time monitoring capabilities
Testing was conducted following adjusted standardized protocols, including the AATCC TM100 standard for antimicrobial performance, with results showing consistent bacterial reduction under active patches compared to controls.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
glenn1919
2月前
maestro_of_Ihub
7月前
81vette
9月前
tedpeele
9月前
luckydude777
11月前
peterus
2年前
メールアドレスで登録
